AlvirJMJ, LiebermanJA, SaffermanAZ, SchwimmerJL, SchaafJA: Clozapine-induced agranulocytosis—Incidence and risk factors in the United States. N Engl J Med, 329:162–167, 1993.
2.
CanitanoR, PallagrosiM: Autism spectrum disorders and schizophrenia spectrum disorders: Excitation/inhibition imbalance and developmental trajectories. Front Psychiatry, 8:69, 2017.
3.
De LacyN, KingBH: Revisiting the relationship between autism and schizophrenia: Toward an integrated neurobiology. Annu Rev Clin Psychol, 9:555–587, 2013.
4.
Gerbino-RosenG, RoofehD, TompkinsDA, FeryoD, NusserL, KranzlerH, NapolitanoB, FredericksonA, HendersonI, RhinewineJ, KumraS: Hematological adverse events in clozapine-treated children and adolescents. J Am Acad Child Adolesc Psychiatry, 44:1024–1031, 2005.
5.
GogtayN, RapoportJ: Clozapine use in children and adolescents. Expert Opin Pharmacother, 9:459–465, 2008.
6.
HäfnerH, MaurerK, LöfflerW, Riecher-RösslerA: The influence of age and sex on the onset and early course of schizophrenia. Br J Psychiatry, 162:80–86, 1993.
7.
KumraS, KranzlerH, Gerbino-RosenG, KesterHM, DeThomasC, CullenK, ReganJ, KaneJM: Clozapine versus “high-dose” olanzapine in refractory early-onset schizophrenia: An open-label extension study. J Child Adolesc Psychopharmacol, 18:307–316, 2008.
LégaréN, GrégoireCA, De BenedictisL, DumaisA: Increasing the clozapine: Norclozapine ratio with co-administration of fluvoxamine to enhance efficacy and minimize side effects of clozapine therapy. Med Hypotheses, 80:689–691, 2013.
10.
LuML, ChenTT, KuoPH, HsuCC, ChenCH: Effects of adjunctive fluvoxamine on metabolic parameters and psychopathology in clozapine-treated patients with schizophrenia: A 12-week, randomized, double-blind, placebo-controlled study. Schizophr Res, 193:126–133, 2018.
11.
LuML, LaneHY, LinSK, ChenKP, ChangWH: Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J Clin Psychiatry, 65:766–771, 2004.
12.
MidbariY, EbertT, KosovI, KotlerM, WeizmanA, RamA: Hematological and cardiometabolic safety of clozapine in the treatment of very early onset schizophrenia: a retrospective chart review. J Child Adolesc Psychopharmacol, 23:516–521, 2013.
13.
National Collaborating Centre for Mental Health: Psychosis and Schizophrenia in Children and Young People: Recognition and Management (No. 155). London, Great Britain, RCPysch Publications, 2013.
14.
PolcwiartekC, NielsenJ: The clinical potentials of adjunctive fluvoxamine to clozapine treatment: A systematic review. Psychopharmacology, 233:741–750, 2016.
15.
RemschmidtHE, SchulzE, MartinM, WarnkeA, TrottGE: Childhood-onset schizophrenia: History of the concept and recent studies. Schizophr Bull,, 20:727–745, 1994.
16.
SchaberG, StevensI, GaertnerHJ, DietzK, Breyer-PfaffU: Pharmacokinetics of clozapine and its metabolites in psychiatric patients: Plasma protein binding and renal clearance. Br J Clin Pharmacol, 46:453–459, 2002.
17.
SzegediA, AnghelescuI, WiesnerJ, SchlegelS, WeigmannH, HärtterS, HiemkeC, WetzelH: Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: Drug monitoring and tolerability data from a prospective clinical trial. Pharmacopsychiatry, 32:148–153, 1999.
18.
van HartenJ: Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet, 29Suppl 1:1–9, 1995.
19.
WestenbergHGM, SandnerC: Tolerability and safety of fluvoxamine and other antidepressants. Int J Clin Pract, 60:482–491, 2006.
20.
YalcinO, KaymakG, ErdoganA, TanidirC, KaracetinG, KilicogluAG, MutluC, AdaletliH, GunesH, BahaliK, AyikB, UneriOS: A retrospective investigation of clozapine treatment in autistic and nonautistic children and adolescents in an inpatient clinic in Turkey. J Child Adolesc Psychopharmacol, 26:815–821, 2016.
